| Calcium Hydroxylapatite Radiesse was FDA approved in December 2006 for the correction of facial wrinkles and folds and for the correction of HIV-associated facial atrophy. The dermal filler is composed of 30% calcium hydroxylapatite and 70% carrier gel. The clinical results from may last as long as 12 months or longer, although the carrier gel lasts no longer than 6 months, thus often resulting in a slight decrease in correction at that time. Radiesse is nearly always injected subdermally. Studies from 2008 suggest that calcium hydroxylapatite may induce neocollagenesis, although further research is needed. Most commonly, Radiesse is used for the correction of nasolabial folds, atrophic cheeks, and temporal wasting. Precautions Injection into the dermis may result in nodule formation and should be avoided. Extreme care must be taken to avoid injection while withdrawing the needle out of the skin, which will result in the deposition of material into the dermis. Treatment of the lips has resulted in cyst or spindle formation. Most aesthetic surgeons avoid treating the lips with Radiesse. |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| Aesthetic Medicine Today |
 | |  | |  | |  | |  | |  |
 | |  | |  | |  | |  | |  |
 | |  | |  |